Video Experimental Relacionado
Updated: Sep 4, 2025
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.4K
El aumento y disminución del apoyo circulatorio mecánico temporal en el choque cardiogénico: una declaración
Circulation
|July 21, 2022
Resumen
El apoyo circulatorio mecánico temporal se utiliza cada vez más para el choque cardiogénico, pero la evidencia es limitada. Esta declaración ofrece orientación práctica sobre la selección del dispositivo, la escalada y el destete para pacientes con insuficiencia cardíaca y ataque cardíaco.
Área de la Ciencia:
- Cardiología
- Medicina de cuidados intensivos
- Apoyo circulatorio mecánico
Sus antecedentes:
- El uso de apoyo circulatorio mecánico temporal (MCS) en el choque cardiogénico está aumentando rápidamente.
- La toma de decisiones clínicas carece de pruebas sólidas de ensayos controlados aleatorios.
- Las directrices de la sociedad profesional para la escalada / desescalada de MCS son escasas.
Objetivo del estudio:
- Proporcionar sugerencias pragmáticas para la selección, la escalada y el destete de dispositivos MCS temporales.
- Ofrecer orientación para pacientes con insuficiencia cardíaca aguda descompensada y infarto agudo de miocardio.
- Establecer enfoques estandarizados para el uso temporal de MCS a la espera de nuevos datos clínicos.
Principales métodos:
- Esta declaración científica sintetiza los conocimientos actuales y las opiniones de los expertos.
- Se centra en las causas comunes del shock cardiogénico.
- Su objetivo es orientar la práctica clínica en ausencia de datos definitivos de ensayos.
Principales resultados:
- Proporciona recomendaciones prácticas para la gestión temporal de la MCS.
- Aborda la selección de dispositivos, la escalada y las estrategias de destete.
- Destaca la necesidad de enfoques estandarizados.
Conclusiones:
- El apoyo circulatorio mecánico temporal es una intervención crítica en el choque cardiogénico.
- Se necesitan estrategias estandarizadas y basadas en la evidencia para obtener resultados óptimos para los pacientes.
- Esta declaración sirve como recurso clínico hasta que estén disponibles más datos aleatorios.
Videos de Conceptos Relacionados
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
70
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
70
01:24Blood Pressure Imbalances and Circulatory Shock
988
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
988
01:22Heart Failure VI: Adjunct Therapies
25
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
01:30Cardiomyopathy II: Dilated Cardiomyopathy
20
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20
01:29Cardiomyopathy V: Interprofessional Care
30
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30